Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Pepys, M. B.
  • Herbert, J.
  • Hutchinson, W. L.
  • Tennent, G. A.
  • Lachmann, H. J.
  • Gallimore, J. R.
  • Lovat, L. B.
  • Bartfai, Tamas
  • Alanine, A.
  • Hertel, C.
  • Hoffmann, T.
  • Jakob-Roetne, R.
  • Norcross, R. D.
  • Kemp, J. A.
  • Yamamura, K.
  • Suzuki, M.
  • Taylor, G. W.
  • Murray, Sarah
  • Thompson, D.
  • Purvis, A.
  • Kolstoe, S.
  • Wood, S. P.
  • Hawkins, P. N.

publication date

  • May 2002

journal

  • Nature  Journal

abstract

  • The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. This mechanism of drug action potently removes SAP from human amyloid deposits in the tissues and may provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.

subject areas

  • Amyloidosis
  • Animals
  • Calcium
  • Carboxylic Acids
  • Cross-Linking Reagents
  • Crystallography, X-Ray
  • Dimerization
  • Humans
  • Inhibitory Concentration 50
  • Liver
  • Mice
  • Models, Molecular
  • Protein Binding
  • Protein Structure, Quaternary
  • Pyrrolidines
  • Serum Amyloid P-Component
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0028-0836

Digital Object Identifier (DOI)

  • 10.1038/417254a

PubMed ID

  • 12015594
scroll to property group menus

Additional Document Info

start page

  • 254

end page

  • 259

volume

  • 417

issue

  • 6886

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support